However, new and exciting NFκB-specific strategies are now being explored for cancer and metabolic diseases and will open new therapeutic opportunities for disease, including cell-specific and phase-specific oscillatory inhibition of NFκB in kidney injury. The gene discussed is NFKB1; the disease is metabolic disease.